泰林生物(300813) - 2021 Q3 - 季度财报

Revenue and Profit - The company's revenue for Q3 2021 reached ¥71,422,325.29, representing a 49.47% increase compared to the same period last year[3]. - Net profit attributable to shareholders was ¥14,721,283.67, a 2.23% increase year-over-year, while the net profit excluding non-recurring items was ¥14,650,031.86, up 24.78%[3]. - The company reported a 36.18% increase in total revenue for the first nine months of 2021, reaching ¥182,460,728.75, driven by growth in microbiological testing and isolation technology series[8]. - Total operating revenue for the third quarter reached ¥182,460,728.75, an increase of 36.2% compared to ¥133,985,425.75 in the same period last year[18]. - Net profit for the period was ¥42,375,107.14, representing a 29.6% increase from ¥32,695,397.00 in the previous year[19]. - Basic and diluted earnings per share were both ¥0.82, compared to ¥0.65 in the same quarter last year[19]. Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥610,714,606.26, reflecting a 13.10% increase from the end of the previous year[3]. - The company's current assets totaled CNY 486,835,516.46, up from CNY 426,284,738.18 at the end of 2020, indicating an increase of about 14.19%[13]. - The total liabilities of the company were CNY 125,574,876.54, compared to CNY 95,748,991.37 at the end of 2020, reflecting an increase of approximately 31.14%[15]. - The non-current assets totaled CNY 123,879,089.80, an increase from CNY 113,708,937.69, reflecting a growth of approximately 8.67%[14]. Cash Flow - The company experienced a net cash outflow from operating activities of ¥-3,459,146.50, a decline of 105.44% compared to the previous year, mainly due to increased payments for goods and services[8]. - Cash flow from operating activities showed a net outflow of ¥3,459,146.50, a significant decrease from a net inflow of ¥63,531,779.40 in the previous year[21]. - The company reported a net cash outflow from investing activities of ¥219,583,053.62, compared to a net outflow of ¥167,127,852.11 in the previous year[23]. - Total cash inflow from operating activities was ¥222,032,822.40, compared to ¥200,894,994.09 in the same period last year[21]. - Cash and cash equivalents at the end of the period totaled ¥85,976,434.68, slightly up from ¥80,309,791.68 at the end of the previous year[23]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 6,418, with the largest shareholder holding 53.49% of the shares[10]. - The total equity attributable to shareholders increased by 9.21% to ¥485,139,729.72 compared to the previous year[4]. - The company's equity attributable to shareholders reached CNY 485,139,729.72, up from CNY 444,244,684.50, indicating a growth of about 9.21%[15]. Research and Development - Research and development expenses for the first nine months of 2021 were ¥36,078,580.13, a 39.17% increase compared to the same period in 2020, driven by investments in new products and technologies[8]. - Research and development expenses increased to ¥36,078,580.13, up from ¥25,924,796.84, reflecting a 39.3% year-over-year growth[18]. Inventory and Receivables - The company reported a significant increase in accounts receivable, which rose by 92.18% to ¥34,351,456.58, primarily due to increased sales of isolation technology products[7]. - Accounts receivable rose significantly to CNY 34,351,456.58 from CNY 17,874,328.92, marking an increase of approximately 92.43% year-over-year[13]. - Inventory levels increased to CNY 118,640,087.07, compared to CNY 63,193,535.61 at the end of 2020, representing an increase of around 87.73%[13]. - The company reported a significant increase in prepayments, which rose to CNY 14,563,910.22 from CNY 7,469,067.11, marking an increase of about 95.66%[13]. Other Information - The company has not reported any new product developments or market expansion strategies in the current quarter[12]. - The company did not undergo an audit for the third quarter report[24].